Sangamo BioSciences | SGMO - Ebit


Sangamo BioSciences reported $-72.22M in EBIT for its fiscal quarter ending in June of 2023.





Ebit Change Date
Alaunos Therapeutics USD -952K 60K Jun/2026
Alnylam Pharmaceuticals USD 179.66M 67.06M Sep/2026
Alterity Therapeutics Limited AUD -8.07M 302.4K Dec/2025
Amgen USD 4.68B 65M Sep/2026
Bayer EUR 129M 626M Sep/2026
BioCryst Pharmaceuticals USD 98.46M 161.92M Jun/2026
Biogen USD 419.5M 663.3M Sep/2026
BioMarin Pharmaceutical USD 205.6M 100M Sep/2026
Cipla INR 10.43B 1.55B Sep/2026
Clal Biotechnology ILS -5.44M 3.76M Dec/2022
Compugen USD -8.84M 180K Jun/2026
CSL USD 2.64B 116M Dec/2025
Gilead Sciences USD 3.85B 1.17B Jun/2026
GlaxoSmithKline GBP 2.86B 251M Sep/2026
Grifols EUR 320.55M 91.01M Dec/2025
Ionis Pharmaceuticals USD -130M 27.71M Sep/2026
J&J USD 6.47B 1B Sep/2026
Karyopharm Therapeutics USD -26.76M 8.92M Mar/2026
Merck USD 7.33B 6.49B Sep/2026
Novartis USD 5.14B 411M Sep/2026
Omeros USD -48.15M 7.25M Sep/2023
Pfizer USD 4.85B 5.03B Sep/2026
Roche Holding CHF 11.46B 1.91B Jun/2026
Sanofi EUR 4.72B 3.6B Sep/2026
Sarepta Therapeutics USD -9.04M 22.33M Sep/2026
Tectonic Therapeutic USD -24.22M 3.08M Jun/2026
Ultragenyx Pharmaceutical USD -110M 35M Sep/2026
Vertex Pharmaceuticals USD 1.26B 11.3M Sep/2026